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Background: Clinical-Diffusion mismatch (CDM; NIHSS score ≥8 & DWI lesion volume ≤25 mL) and Perfusion-
Diffusion mismatch (PDM; difference >20% between initial DWI and MTT lesion volumes) have been proposed as
surrogates for ischemic brains that are at risk of infarction. However, their utility to improve the selection of patients
for thrombolytic treatment remains controversial. Our aim was to identify molecular biomarkers that can be used
with neuroimaging to facilitate the selection of ischemic stroke patients for systemic thrombolysis.
Methods: We prospectively studied 595 patients with ischemic stroke within 12 h of the stroke onset. A total of
184 patients received thrombolytic treatment according to the SITS-MOST criteria. DWI and MTT volumes were
measured at admission. The main outcome variable was good functional outcome at 3 months (modified Rankin
scale <3). Serum levels of glutamate (Glu), IL-10, TNF-α, IL-6, NSE, and active MMP-9 also were determined at
admission.
Results: Patients treated with t-PA who presented with PDM had higher IL-10 levels at admission (p < 0.0001). In
contrast, patients with CDM had higher levels of IL-10 (p < 0.0001) as well as Glu and TNF-α (all p < 0.05) and lower
levels of NSE and active MMP-9 (all p < 0.0001). IL-10 ≥ 30 pg/mL predicts good functional outcome at 3 months
with a specificity of 88% and a sensitibity of 86%. IL-10 levels ≥30 pg/mL independently in both patients with PDM
(OR, 18.9) and CDM (OR, 7.5), after an adjustment for covariates.
Conclusions: Serum levels of IL-10 facilitate the selection of ischemic stroke patients with CDM and PDM for
systemic thrombolysis.
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Systemic thrombolysis during the first 4.5 hours after
the onset of a stroke is the gold standard for the treat-
ment of acute ischemic stroke. However, t-PA has been
linked to severe side effects, can be applied only in a re-
stricted number of patients, and has only moderate effi-
cacy. Further criteria need to be developed that may
expand the time window for treatment. Neuroimaging
methods have been developed in recent years to identify* Correspondence: miguel.blanco.gonzalez2@sergas.es
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distribution, and reproduction in any mediumthe presence of ischemic brain tissue that is still viable.
The identification of this at-risk tissue would increase the
therapeutic window beyond 4.5 hours and improve the
selection of patients for recanalization. The perfusion-
diffusion mismatch (PDM) model has been the most fre-
quently used to identify at-risk tissue. However, in addition
to technical difficulties, the cost effectiveness of PDM is
limited, and recent studies have challenged its utility in
selecting patients for systemic thrombolysis [1-3]. Our
group has previously proposed the clinical-diffusion mis-
match (CDM) as a simplified alternative method to select
patients for thrombolytic therapy [4]. CDM is based on
the supposition that patients with severe neurological defi-
cits (NIHSS ≥8) but relatively small lesion volumes on dif-
fusion weighted images (DWI volume <25 mL) are likely
to have enough of an ischemic penumbra to benefit fromd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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have confirmed the utility of CDM [5-7]. However, the
usefulness of CDM to improve the selection of patients
for thrombolytic treatment has not been confirmed.
Moreover, previous studies by our group have demon-
strated that salvageable brain, which is defined as the
presence of CDM, may be predicted by a number of mo-
lecular signatures of ischemic but non-infarcted brain.
Specifically, higher levels of IL-10, TNF-α and Glu as
well as lower levels of NSE, IL-6 and active MMP-9 have
been associated with the presence of CDM [8].
Our aim was to study whether serum levels of several
biomarkers could facilitate the selection of ischemic stroke
patients with CDM or PDM for systemic thrombolytic
treatment with t-PA.
Methods
Study population and patients characteristics
We prospectively evaluated 835 consecutive patients with
hemispheric ischemic stroke who were admitted to two
university hospitals within the first 12 hours of their stroke
onset. Patients who presented with stroke on awakening
(n = 38), severe systemic disease (n = 27), dementia (n = 9),
lesions located within the vertebrobasilar territory (n =
13), psychiatric disease (n = 9), chronic inflammatory dis-
ease (n = 21), or active infection (n = 11), or were enrolled
in other clinical trials (n = 55), refused to participate in
the study (n = 4), had technical problems with the MRI
(n = 9), were lost to follow-up (n = 36) or were undergo-
ing other recanalization procedures (n = 8) were ex-
cluded from the study. Therefore, a total of 595 patients
were included in the study.
The Local Ethical Committees of the Clinical University
Hospital of Santiago de Compostela and the Clinical
University Hospital Doctor Josep Trueta of Girona ap-
proved the protocol. All patients or their relatives gave
signed informed consent.
Clinical variables and neuroimaging studies
All patients were treated according to the guidelines for
the management of ischemic stroke from the European
Stroke Organization (ESO) [9]. A total of 184 patients
received thrombolytic treatment with t-PA within the
first 3 hours of the stroke onset following the SITS-
MOST criteria [10]. Demographic data (age, sex), and a
prior history of high blood pressure, diabetes, heart dis-
ease, hyperlipidemia, alcohol consumption and smoking
were recorded. At admission, a blood sample was col-
lected to determine the blood count as well as other
biochemistry and molecular markers, and diffusion-
weighted (DWI) and perfusion-weighted (PWI) magnetic
resonance imaging (MRI) was performed. The stroke
subtype was classified according to the TOAST criteria
[11] once carotid and transcranial ultrasounds andancillary studies were completed. The National Institute
of Health Stroke Scale (NIHSS) score (admission, 24 h,
48 h, 72 h and 90 ± 7 days) and the modified Rankin
Scale (mRS) (90 ± 7 days) were evaluated by certified in-
vestigators. The functional outcome was categorized as
good (mRS <3) or poor (mRS ≥3).
MR images were obtained at admission on a 1.5 T sys-
tem (Intera, Philips, Best, The Netherlands) or a 1.5
Magneton Symphony (Siemens, Er- langen, Germany)
with echoplanar capabilities of 25-mT/m gradients and
300- to 350-microsecond rise times. The MRI protocol
included DWI, T2-weighted, and fluid-attenuated inver-
sion recovery (FLAIR) imaging. The DWI sequence was
performed with a b value of 1,000 and was analysed in
the trace image to avoid anisotropy. The PWI lesion
volume was measured using mean transient time (MTT)
maps with a 4-second threshold. PDM was defined as
positive when the difference between the DWI and MTT
lesion volumes was >20%. Based on previous studies, we
defined the presence of CDM as an NIHSS score ≥ 8 at
admission and a lesion volume during the baseline DWI <
25 mL [4]. A second MRI to evaluate the DWI volume
was performed 72 ± 12 hours in all patients that received
thrombolytic therapy, except in 6 patients who died. We
evaluated the infarct growth as the percentage difference
in DWI volume between the basal MRI (DWI 0 h) and the
control MRI (DWI 72 h) according to the following
formula: (DWI 72 h - DWI 0 h)/DWI 0 h × 100.
A neuroradiologist who was blind to the clinical data
evaluated the DWI and MTT volumes by manual seg-
mentation method.
Laboratory test
Blood samples, which were obtained from all patients at
admission before thrombolytic therapy, were collected in
chemistry test tubes, centrifuged at 3000 g for 15 minutes,
and immediately frozen and stored at −80°C. Serum levels
of interleukin (IL)-6 and tumour necrosis factor (TNF)-α
were measured using an immunodiagnostic IMMULITE
1000 System (Diagnostic Products Corporation, California,
USA). Neuron-specific enolase (NSE) serum levels were
determined by electrochemiluminescence immunoassay
using an analyser ELECSYS 2010 (Roche Diagnostics
GmbH, Mannheim, Germany). Likewise, the serum levels
of IL-10 (Bender Medsystems GmbH, Vienna, Austria) as
well as the active metalloproteinase-9 (MMP-9) (GE
Healthcare - Amersham, Little Chalfont Buckinghamshire,
UK) were measured using commercial ELISA kits follow-
ing the manufacturer instructions. Serum levels of glu-
tamate (Glu) were determined by high performance liquid
chromatography (HPLC) analysis following a previously
described method [12]. The intra-assay and inter-assay
coefficients of variation (CV) for each molecular marker
are reported in Additional file 1: Table S1. Determinations
Figure 1 Median [quartiles] of the modified Rankin Scale (mRS) scores in patients who either received or did not receive thrombolytic
treatment. Figure A shows patients with and without perfusion-diffusion mismatch (PDM) and Figure B shows patients with and without
clinical-diffusion mismatch (CDM).
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ical and neuroimaging data.
Statistical analysis
Results are expressed as percentages for the categorical
variables and as either the mean (SD) or median [quar-
tiles] for the continuous variables depending on whether
or not, respectively, the data followed a normal distribu-
tion. Proportions were compared using the chi-square
test. The Student’s t test (normal data) or the Mann–
Whitney test (non-normal data) was used to compare
continuous variables between 2 groups, and the ANOVA
test was used to compare across more than 2 groups. Bi-
variate correlations were determined by the Pearson’s
correlation coefficient. ROC curves were configured to
establish cut-off points for molecular marker levels that
optimally predicted good functional outcome.
Due to the colinearity between the molecular markers,
the influence of each marker on the functional outcome at
3 months was assessed in a separate logistic regression
model and adjusted for the main baseline variables thatTable 1 Molecular profiles of patients with perfusion-diffusio
who received or did not receive thrombolytic treatment
PDM (n = 100)
NO (n = 21) YES (n = 79)
NSE (ng/mL) 22.4 ± 9.0 20.7 ± 6.1
IL-10 (pg/mL) 8.8 ± 7.0 22.5 ± 14.9 <
Glutamate (μM) 150.9 ± 102.2 207.7 ± 177.9
IL-6 (pg/mL) 9.9 ± 8.9 11.9 ± 8.6
TNF-α (pg/mL) 10.3 ± 6.3 11.5 ± 8.2
MMP-9 (ng/mL) 24.0 ± 16.6 21.0 ± 11.9were related to good functional outcome (mRS <3) in the
univariate analyses (p < 0.05). Results were expressed as
adjusted odds ratios (OR) with the corresponding 95%
confidence intervals (95% CI). Statistical analyses were
conducted using SPSS 16.0 for Mac.
Results
All patients had DWI-MRI performed at admission, and
237 patients (39.8%) had PWI-MRI performed at admis-
sion. CDM was found in 244 patients (41.0%) and PDM
in 189 of 237 patients (79.7%).
No differences in functional outcome at 3 months
were found in patients with or without CDM or PDM
who did not received thrombolytic therapy. However,
patients with CDM who received thrombolytic treatment
showed a better outcome than patients without CDM (3
[1,4] vs. 2 [0,3], p = 0.001). In contrast, a good functional
outcome at 3 months was independent of PDM status (2
[1,4] vs. 3 [1,4], p = 0.361) (Figure 1).
A total of 184 patients (30.9%) received thrombolytic
treatment according to the SITS-MOST criteria. Patientsn mismatch (PDM) and clinical-diffusion mismatch (CDM)
CDM (n = 184)
p NO (n = 92) YES (n = 92) p
0.449 24.6 ± 8.3 21.4 ± 5.8 0.002
0.0001 8.6 ± 8.0 30.9 ± 14.7 <0.0001
0.290 152.5 ± 91.5 226.6 ± 186.9 0.031
0.250 20.9 ± 17.7 14.2 ± 7.6 0.109
0.774 12.4 ± 6.6 18.4 ± 12.6 0.003
0.745 29.6 ± 18.4 20.2 ± 8.4 <0.0001
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had higher IL-10 levels at admission. In contrast, pa-
tients with CDM had higher levels of IL-10 as well as
Glu and TNF-α and lower levels of NSE and active
MMP-9 (Table 1).
Table 2 shows the baseline characteristics of patients
who received thrombolytic treatment by outcome group.
A good outcome was observed in 103 patients (56.0%) and
a poor outcome was observed in 81 patients (44.0%). Pa-
tients with a good outcome were younger and had lower
stroke severity and smaller DWI and MTT volumes at ad-
mission compared with patients with a poor outcome.
The only molecular marker that was independentlyTable 2 Baseline characteristics of patients who received thro
Poor outcome (n = 81
Age, years 71.4 ± 9.3
Male gender, % 54.3
Time from stroke onset, minutes 84.7 ± 36.4
TOAST
- Atherothrombotic, n (%) 16.0
- Cardioembolic, n (%) 59.3
- Lacunar, n (%) 0
- Undetermined, n (%) 24.7
History of hypertension, n (%) 59.3
History of diabetes, n (%) 12.3
History of dyslipemia, n (%) 21.0
Smoking history, n (%) 14.8
Alcohol consumption, n (%) 6.2
History of coronary disease, n (%) 11.1
History of atrial fibrillation, n (%) 35.8
Previous stroke or TIA, n (%) 14.8
Systolic blood pressure, mmHg 159.1 ± 24.4
Diastolic blood pressure, mmHg 86.7 ± 16.5
Body temperature, °C 36.2 ± 2.3
Glucose levels, mg/dL 129.5 ± 32.2
Leukocytes, 103/mL 8.2 ± 2.3
Platelets, 103/mL 223.6 ± 64.0
Fibrinogen, mg/dL 433.7 ± 114.7
NIHSS at admission 18 [14, 20]
DWI volume at admission, mL 56.0 ± 60.2
MTT volume at admission, mL 143.2 ± 87.4
Neuron-specific enolase (ng/mL) 23.8 ± 7.4
Interleukin-10 (pg/mL) 12.9 ± 10.7
Tumor necrosis factor-α (pg/mL) 13.8 ± 8.7
Interleukin-6 (pg/mL) 21.1 ± 17.3
Active metalloproteinase-9 (ng/mL) 27.8 ± 17.7
Glutamate (μM) 212.7 ± 147.5associated with a good outcome in patients treated with t-
PA was IL-10, which was significantly associated with a
good outcome in patients with PDM (OR: 1.08, CI 95%:
1.94-17.22) as well as CDM (OR: 1.09, CI 95%: 1.04-1.13).
We found that an IL-10 level ≥ 30 pg/mL predicts a good
functional outcome at 3 months with a specificity of 88%
and a sensibility of 86% (area under the curve, 0.952; p <
0.0001).
Figure 2 shows the distribution of mRS scores in the
thrombolytic patients with PDM and CDM categorized
by IL-10 levels. Patients with PDM who also had IL-10
levels ≥30 mg/mL had a good outcome more frequently
than patients with PDM with lower IL-10 levels (72.7 vs.mbolytic treatment by outcome groups
) Good outcome (n = 103) p
64.3 ± 13.5 <0.0001
61.2 0.370














155.6 ± 27.6 0.327
83.5 ± 15.1 0.180
36.4 ± 0.4 0.218
126.3 ± 40.0 0.142
8.7 ± 2.9 0.349
247.3 ± 86.7 0.086
412.6 ± 138.3 0.069
11 [7, 16] <0.0001
16.7 ± 20.2 <0.0001
72.3 ± 79.9 <0.0001
22.4 ± 7.2 0.202
25.1 ± 17.9 <0.0001
16.7 ± 11.5 0.057
14.8 ± 9.9 0.002
22.6 ± 12.1 0.026
171.4 ± 152.6 0.065
Figure 2 Distribution of the modified Rankin Scale (mRS) scores in thrombolytic patients with PDM and CDM categorized by
IL-10 levels.
Table 3 Logistic regression model including those
variables that were significant in the univariate model
forcing the inclusion of DWI volume at admission (model 1)
and DWI volume and NIHSS score and admission (model 2)
Rodríguez-Yáñez et al. BMC Neurology 2013, 13:62 Page 5 of 7
http://www.biomedcentral.com/1471-2377/13/6231.6%, p = 0.002). Similar results were found for patients
with CDM and IL-10 levels ≥30 mg/mL (86.4 vs. 50.0%,
p < 0.0001). In the logistic regression model, IL-10 levels
≥30 mg/mL were independently associated with a good
functional outcome at 3 months in patients with PDM
(OR: 18.88, CI 95%: 3.13-53.03) and CDM (OR: 7.47, CI
95%: 2.52-22.12), after adjusting for age and NIHSS at
admission (The DWI volume was not included in this
model because it is a surrogate variable of CDM and
PDM. However, in a logistic regression model that in-
cluded DWI volume at admission, the IL-10 levels main-
tain independence. These data are shown in Table 3).
In patients who were treated with t-PA, IL-10 serum
levels were negatively correlated with an increase in
DWI volume during the first 72 hours (Pearson’s coeffi-
cient = −0.330, p < 0.0001). This increase in DWI volume
during the first 72 hours was associated with higher glu-
tamate levels (Pearson’s coefficient = 0.336, p < 0.0001).
This correlation between glutamate levels and an increase
in DWI volume during the first 72 hours was higher in
patients with IL-10 levels <30 mg/mL (Pearson’s coeffi-
cient = 0.613, p < 0.0001) and disappeared in patients
with IL-10 levels ≥30 mg/mL (Pearson’s coefficient =
0.193, p = 0.056).Model 1 OR CI 95%
IL-10 levels 1.05 1.01-1.08
IL-10 ≥30 pg/mL 2.86 1.06-7.82
DWI volume 0.98 0.97-0.98
Model 2 OR CI 95%
IL-10 levels 1.07 1.03-1.11
IL-10 ≥30 pg/mL 3.14 1.04-9.51
DWI volume 0.99 0.99-1.00
NIHSS score 0.77 0.73-0.81Discussion
We have found that IL-10 levels are associated with the
presence of PDM and CDM, and that IL-10 levels
≥30 pg/mL are independently associated with a good
outcome in thrombolytic patients with both PDM and
CDM. Therefore, IL-10 serum levels may be used in
combination with PDM or CDM to improve the selec-
tion of patients for recanalization because patients withCDM or PDM and IL-10 ≥30 mg/mL have a better func-
tional outcome at 3 months.
The value of PDM is controversial. Currently, no evi-
dence exists to support or refute its significance in the
diagnosis of ischemic stroke [2]. Several studies have
found that PDM is not associated with either functional
outcome or infarct growth in patients with ischemic
stroke with or without tPA treatment [13,14]. CDM is a
more accessible and simple technique. Although some
studies have failed to find an association between CDM
and functional outcome after thrombolytic therapy [15],
other studies have found that the presence of CDM is
associated with a better functional outcome after t-PA
treatment, even in cases in which t-PA treatment has
been conducted beyond the 3-hour therapeutic window
[7,16,17]. Therefore, the utility of CDM for the selection
of ischemic stroke patients for thrombolytic treatment
remains unclear.
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nostic and prognostic factors in acute ischemic stroke. In
our study, we selected molecular markers that are associ-
ated with infarcted brain tissue, including IL-6 [18], NSE
[19] and MMP-9 [20], as well as molecular markers that
are associated with ischemic penumbra, including IL-10,
TNF-α and glutamate [21,22]. We found that patients with
CDM had higher levels of IL-10, TNF-α and Glu, which
indicates more tissue in the ischemic penumbra, as well as
lower levels of NSE and MMP-9, which indicates lower
levels of infarcted tissue. These findings suggest that CDM
is an appropriate marker of at-risk brain tissue, as we have
observed previously [8]. In contrast, our results showed
that patients with PDM had higher levels of IL-10 only.
Therefore, these results suggest that PDM is a worse sur-
rogate than CDM for the detection of at-risk brain tissue.
Only IL-10 levels were independently associated with a
good functional outcome in thrombolytic patients with
CDM and PDM. Therefore, we conclude that this mo-
lecular marker is the best marker to identify at-risk brain
tissue. IL-10 is an anti-inflammatory molecule that is
secreted mainly by the lymphocytes and monocytes/
macrophages to block pro-inflammatory actions [23].
Several studies have shown the neuroprotective effects
of the administration of IL-10 in experimental models of
cerebral ischemia [24,25]. Furthermore, patients with
better clinical outcomes have shown higher IL-10 levels
[26]. In our study, we have observed a negative correl-
ation between IL-10 levels and infarct growth, which fur-
ther suggests a neuroprotective effect of IL-10. Patients
with lower IL-10 levels also showed greater infarct
growth during the first 72 hours following the onset of
the stroke. Our results showed a correlation between
glutamate levels and DWI lesion growth, which suggests
that this increase in infarct volume is associated with an
excitotoxic effect of Glu. However, this association dis-
appears in patients with IL-10 levels ≥30 mg/mL, which
suggests a possible neuroprotective effect that blocks
these excitotoxic mechanisms. More studies are needed
to confirm these results. Another possible explanation is
that high levels of IL-10 may be associated with a higher
rate of recanalization. However, we cannot confirm this
theory with our study because we do not have data on
recanalization after rtPA therapy.
A routine test for IL-10 does not exist. Currently, IL-10
levels are determined by commercial ELISA kits. However,
this method is simple and inexpensive and could be used
in the future within Emergency Departments to facilitate
the selection of candidates for recanalization therapies.
Our study has some limitations. First, PWI-MRI was
performed in a small percentage of patients. This small
sample size may have prevented us from reaching
statistical significance to identify the utility of PDM
in selecting patients for revascularization techniques.Second, this exploratory study has not prospectively in-
vestigated an a priori hypothesis. Therefore, these results
should be confirmed in future studies. Finally, we did
not control for potential confounding variables, such as
pre-treatment with statins, which may interfere with
molecular marker levels.
In conclusion, IL-10 levels ≥30 mg/mL increase the
ability to identify salvageable brain tissue in patients with
CDM and PDM and facilitates the selection of ischemic
stroke patients for systemic thrombolysis.
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